13 results about "Cyclobenzaprine" patented technology

The present disclosure provides a method for treating post-acute sequelae of severe acute respiratory syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, said method comprising administering to a subject in need thereof or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The present disclosure provides, in some embodiments, a method and a pharmaceutical composition for treating post-acute sequelae of (SARS)-CoV-2 infection (PASC) or one or more symptoms associated therewith in a subject in need thereof or at risk thereof, wherein said pharmaceutical composition comprises a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of a cyclobenzaprine intermediate 5H-dibenzo [a, d] cycloheptatriene-5-ketone. The preparation method comprises the following steps: preparing a magnesium Grignard reagent by taking 2-(2-chlorine or bromostyrene) benzonitrile as an initial raw material, and performing intramolecular cyclization and acidification to obtain a target compound I; the whole process is moderate in reaction temperature and mild in condition, use of expensive catalysts and special production equipment is avoided, and the production cost can be effectively reduced; meanwhile, the use of carbon tetrachloride and bromine with higher toxicity is avoided, the operation is safe, and the method is more suitable for industrial application.

Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and / or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75%±2% by weight cyclobenzaprine HCl and 25%±2% by weight β-mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

The present disclosure relates to methods for treating or preventing one or more of acute stress reaction (ASR), acute stress disorder (ASD), or one or more associated symptoms using a pharmaceutical composition comprising cyclobenzaprine or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods for treating or preventing ASR, ASD, or one or more associated symptoms in a subject who has experienced a traumatic event within about 1, 2, 3, 4, 5, 6, or 7 days prior to the commencement of treatment. The present disclosure also relates to methods for preventing the onset of post-traumatic stress disorder and for improving recovery from stress occasioned by a traumatic event.

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75% ± 2% by weight cyclobenzaprine HCl and 25% ± 2% by weight β‑mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

The present disclosure provides methods for treating post acute sequelae (PASC) of severe acute respiratory syndrome (SARS)-CoV-2 infection, or one or more symptoms associated with PASC, comprising administering a pharmaceutical composition to a subject in need thereof or at risk thereof, the pharmaceutical composition comprises a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

The present invention relates to methods of treating post-traumatic stress disorders and acute stress disorders using a pharmaceutical composition comprising cyclobenzaprine, amitriptyline, or a pharmaceutically acceptable salt thereof. In particular, the present invention relates to methods of treating post-traumatic stress disorder, or one or more symptoms thereof, in a subject having undergone a traumatic event of less than or equal to about 9 years prior to initiation of treatment. The present invention also relates to methods of treating acute stress disorder or one or more symptoms thereof in a subject having undergone a traumatic event of less than or equal to about 1 month prior to initiation of treatment.

A composition for treatment of pain and inflammation in humans includes 4.0-10.0% Diclofenac Sodium by weight, 2.0-6.0% Gabapentin by weight, 1.0-2.0% Baclofen by weight, and 2.0-5.0% Cyclobenzaprine by weight. Other compositions are also disclosed.

The invention provides compositions and methods for administering therapeutic compounds, particularly cyclobenzaprine or amitriptyline, for absorption through the mucosa, wherein the compositions contain a basifying agent in addition to the therapeutic agent. The compositions and methods have a number of unexpected pharmacokinetic benefits over oral administration. Methods of treating fibromyalgia in a human subject are also provided.

The present invention relates to a cyclobenzaprine hydrochloride sustained-release capsule. The content of the sustained-release capsule includes sustained-release coated pellets, and the sustained-release coated pellets are made of blank cores and drug-containing sustained-release coating layers. The drug-containing sustained-release coating layer includes cyclobenzaprine hydrochloride and a sustained-release material. The coating solvent used in the coating process of the sustained-release coated pellets does not contain ethanol or water. The cyclobenzaprine hydrochloride sustained-release capsule prepared by the present invention not only has a similar in vitro release rate to the original research formulation, but also has good chemical stability, ensuring the safety and effectiveness of clinical medication.